Selected research
Industry Research
Assisted Reproduction Drug Industry Research Report 2026
Market perspective
The global Assisted Reproduction Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Assisted Reproduction Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Assisted Reproduction Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Assisted Reproduction Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Assisted Reproduction Drug include Ipsen Pharma Biotech, Zhejiang Xianju Pharmaceutical Co., Ltd., Solvay Pharma, Shanghai First Biochemical Pharmaceutical Co. LTD, Merck Sharp & Dohme, Merck Serono, Livzon Group and GenSci, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Assisted Reproduction Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Assisted Reproduction Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Assisted Reproduction Drug Market by Company
Ipsen Pharma Biotech
Zhejiang Xianju Pharmaceutical Co., Ltd.
Solvay Pharma
Shanghai First Biochemical Pharmaceutical Co. LTD
Merck Sharp & Dohme
Merck Serono
Livzon Group
GenSci
Assisted Reproduction Drug Segment by Type
Progestogen Hormone
Human Choroinic Gonadotrophin
Gonadotropin Releasing Hormone
Follicle-stimulating Hormone
Assisted Reproduction Drug Segment by Application
Controlled Ovarian Hyperstimulation
luteal Support
Down Regultion
Induced Ovulation
Assisted Reproduction Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Assisted Reproduction Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Assisted Reproduction Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Assisted Reproduction Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Assisted Reproduction Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Progestogen Hormone
- Human Choroinic Gonadotrophin
- Gonadotropin Releasing Hormone
- Follicle-stimulating Hormone
Applications
- Controlled Ovarian Hyperstimulation
- luteal Support
- Down Regultion
- Induced Ovulation
Companies covered
- Ipsen Pharma Biotech
- Zhejiang Xianju Pharmaceutical Co., Ltd.
- Solvay Pharma
- Shanghai First Biochemical Pharmaceutical Co. LTD
- Merck Sharp & Dohme
- Merck Serono
- Livzon Group
- GenSci
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Assisted Reproduction Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Progestogen Hormone
- 2.2.3 Human Choroinic Gonadotrophin
- 2.2.4 Gonadotropin Releasing Hormone
- 2.2.5 Follicle-stimulating Hormone
- 2.3 Assisted Reproduction Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Controlled Ovarian Hyperstimulation
- 2.3.3 luteal Support
- 2.3.4 Down Regultion
- 2.3.5 Induced Ovulation
- 2.4 Assumptions and Limitations
3 Assisted Reproduction Drug Breakdown Data by Type
- 3.1 Global Assisted Reproduction Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Assisted Reproduction Drug Forecasted Market Size by Type (2027-2032)
4 Assisted Reproduction Drug Breakdown Data by Application
- 4.1 Global Assisted Reproduction Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Assisted Reproduction Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Assisted Reproduction Drug Market Perspective (2021-2032)
- 5.2 Global Assisted Reproduction Drug Growth Trends by Region
- 5.2.1 Global Assisted Reproduction Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Assisted Reproduction Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Assisted Reproduction Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Assisted Reproduction Drug Market Dynamics
- 5.3.1 Assisted Reproduction Drug Industry Trends
- 5.3.2 Assisted Reproduction Drug Market Drivers
- 5.3.3 Assisted Reproduction Drug Market Challenges
- 5.3.4 Assisted Reproduction Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Assisted Reproduction Drug Players by Revenue
- 6.1.1 Global Top Assisted Reproduction Drug Players by Revenue (2021-2026)
- 6.1.2 Global Assisted Reproduction Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Assisted Reproduction Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Assisted Reproduction Drug Head Office and Area Served
- 6.4 Global Assisted Reproduction Drug Players, Product Type & Application
- 6.5 Global Assisted Reproduction Drug Manufacturers Established Date
- 6.6 Global Assisted Reproduction Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Assisted Reproduction Drug Market Size (2021-2032)
- 7.2 North America Assisted Reproduction Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Assisted Reproduction Drug Market Size by Country (2021-2026)
- 7.4 North America Assisted Reproduction Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Assisted Reproduction Drug Market Size (2021-2032)
- 8.2 Europe Assisted Reproduction Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Assisted Reproduction Drug Market Size by Country (2021-2026)
- 8.4 Europe Assisted Reproduction Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Assisted Reproduction Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Assisted Reproduction Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Assisted Reproduction Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Assisted Reproduction Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Assisted Reproduction Drug Market Size (2021-2032)
- 10.2 South America Assisted Reproduction Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Assisted Reproduction Drug Market Size by Country (2021-2026)
- 10.4 South America Assisted Reproduction Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Assisted Reproduction Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Assisted Reproduction Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Assisted Reproduction Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Assisted Reproduction Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Ipsen Pharma Biotech
- 12.1.1 Ipsen Pharma Biotech Company Information
- 12.1.2 Ipsen Pharma Biotech Business Overview
- 12.1.3 Ipsen Pharma Biotech Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.1.4 Ipsen Pharma Biotech Assisted Reproduction Drug Product Portfolio
- 12.1.5 Ipsen Pharma Biotech Recent Developments
- 12.2 Zhejiang Xianju Pharmaceutical Co., Ltd.
- 12.2.1 Zhejiang Xianju Pharmaceutical Co., Ltd. Company Information
- 12.2.2 Zhejiang Xianju Pharmaceutical Co., Ltd. Business Overview
- 12.2.3 Zhejiang Xianju Pharmaceutical Co., Ltd. Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.2.4 Zhejiang Xianju Pharmaceutical Co., Ltd. Assisted Reproduction Drug Product Portfolio
- 12.2.5 Zhejiang Xianju Pharmaceutical Co., Ltd. Recent Developments
- 12.3 Solvay Pharma
- 12.3.1 Solvay Pharma Company Information
- 12.3.2 Solvay Pharma Business Overview
- 12.3.3 Solvay Pharma Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.3.4 Solvay Pharma Assisted Reproduction Drug Product Portfolio
- 12.3.5 Solvay Pharma Recent Developments
- 12.4 Shanghai First Biochemical Pharmaceutical Co. LTD
- 12.4.1 Shanghai First Biochemical Pharmaceutical Co. LTD Company Information
- 12.4.2 Shanghai First Biochemical Pharmaceutical Co. LTD Business Overview
- 12.4.3 Shanghai First Biochemical Pharmaceutical Co. LTD Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.4.4 Shanghai First Biochemical Pharmaceutical Co. LTD Assisted Reproduction Drug Product Portfolio
- 12.4.5 Shanghai First Biochemical Pharmaceutical Co. LTD Recent Developments
- 12.5 Merck Sharp & Dohme
- 12.5.1 Merck Sharp & Dohme Company Information
- 12.5.2 Merck Sharp & Dohme Business Overview
- 12.5.3 Merck Sharp & Dohme Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.5.4 Merck Sharp & Dohme Assisted Reproduction Drug Product Portfolio
- 12.5.5 Merck Sharp & Dohme Recent Developments
- 12.6 Merck Serono
- 12.6.1 Merck Serono Company Information
- 12.6.2 Merck Serono Business Overview
- 12.6.3 Merck Serono Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.6.4 Merck Serono Assisted Reproduction Drug Product Portfolio
- 12.6.5 Merck Serono Recent Developments
- 12.7 Livzon Group
- 12.7.1 Livzon Group Company Information
- 12.7.2 Livzon Group Business Overview
- 12.7.3 Livzon Group Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.7.4 Livzon Group Assisted Reproduction Drug Product Portfolio
- 12.7.5 Livzon Group Recent Developments
- 12.8 GenSci
- 12.8.1 GenSci Company Information
- 12.8.2 GenSci Business Overview
- 12.8.3 GenSci Revenue in Assisted Reproduction Drug Business (2021-2026)
- 12.8.4 GenSci Assisted Reproduction Drug Product Portfolio
- 12.8.5 GenSci Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst